Vor Bio Secures $491.5M Runway, Advances Phase 3 Telitacicept Trials with H1 2027 Data
Vor Bio ended Q1 2026 with $491.5M cash runway into early 2029 and recorded a $219.6M net loss driven by warrant fair-value changes, versus $32.5M a year earlier. Global Phase 3 trials of telitacicept in generalized myasthenia gravis and Sjögren’s disease are ongoing, with gMG topline data due H1 2027.
1. First Quarter Financial Results
Vor Bio reported cash, cash equivalents and marketable securities of $491.5 million as of March 31, 2026, projected to fund operations into early 2029. R&D expenses were $17.6 million versus $26.7 million in Q1 2025, while G&A expenses rose to $17.6 million from $6.6 million, leading to a net loss of $219.6 million compared to $32.5 million a year earlier, driven largely by changes in warrant liability fair value.
2. Phase 3 Telitacicept Trials
Enrollment continues in the global randomized, double-blind, placebo-controlled Phase 3 UPSTREAM MG trial with an open-label extension assessing telitacicept in generalized myasthenia gravis patients. Enrollment is also ongoing in the UPSTREAM SjD trial for primary Sjögren’s disease, and topline results from the gMG study are expected in the first half of 2027.
3. Strategic Outlook
Management highlights growing clinician interest in upstream B-cell modulation via dual BAFF/APRIL inhibition as a potentially earlier intervention in autoimmune disease treatment. Confidence in telitacicept’s potential to become a foundational therapy underpins plans for global development and future regulatory submissions in the United States, Europe and Japan.